Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226954
Status:
TERMINATED
Last Update Posted:
2020-03-18
First Post:
2005-09-13
Brief Title:
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently
Secondary Objectives
To describe the safety and tolerability at this dose and schedule
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently
Secondary Objectives
To describe the safety and tolerability at this dose and schedule
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PROS0001 | None | None | None |
| 78869 | None | None | None |
| NCT00226954 | None | None | None |